Literature DB >> 23940455

Effects of low-dose hydroxychloroquine on expression of phosphorylated Akt and p53 proteins and cardiomyocyte apoptosis in peri-infarct myocardium in rats.

Jing Zhou1, Gang Li, Zhi-Hua Wang, Li-Ping Wang, Pu-Jiang Dong.   

Abstract

BACKGROUND: Low-dose hydroxychloroquine (HCQ) and ataxia-telangiectasia-mutated (ATM) protein kinase have recently been postulated to be beneficial for the prevention of the age-associated metabolic syndrome including hypertension, hypercholesterolemia and glucose intolerance; however, the effects of low-dose HCQ on the expression of ATM downstream phosphorylated Akt (protein kinase B) and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium remain unclear.
OBJECTIVE: To explore the effects of low-dose HCQ on the expression of phosphorylated Akt and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium in a rat model.
METHODS: Myocardial infarction (MI) was induced experimentally in a subset of rats, while others underwent sham operation (sham). Three days after operation, surviving Sprague-Dawley male rats were divided into MI+HCQ, MI, sham+HCQ and sham groups. MI+HCQ and sham + HCQ groups were treated with HCQ (3.4 mg/kg); and MI and sham groups were treated with phosphate buffered (ie, physiological) saline (10 mL/kg) by gavage every day for 12 weeks. The expression of phosphorylated Akt and p53 proteins and cardiomyocyte apoptosis in the peri-infarct myocardium was detected by Western blot and terminal deoxynucleotidyl transferase dUTP nick end labelling, respectively.
RESULTS: Twelve weeks after treatment, the expression of phosphorylated Akt protein was significantly increased (P<0.05). Expression of phosphorylated p53 protein was not significantly different (P>0.05) in the peri-infarct myocardium of the MI+HCQ group from that in the MI group. The cardiomyocyte apoptosis rate in the peri-infarct myocardium was significantly decreased in the MI+HCQ group compared with the MI group (P<0.05).
CONCLUSION: Low-dose HCQ can significantly increase the expression of phosphorylated Akt protein without significantly impacting expression of phosphorylated p53 protein in the peri-infarct myocardium. Accordingly, it can inhibit cardiomyocyte apoptosis in the peri-infarct myocardium.

Entities:  

Keywords:  Akt (protein kinase B); Cardiomyocyte apoptosis; Hydroxychloroquine (HCQ); Myocardial infarction (MI); P53 (protein 53)

Year:  2013        PMID: 23940455      PMCID: PMC3718607     

Source DB:  PubMed          Journal:  Exp Clin Cardiol        ISSN: 1205-6626


  18 in total

Review 1.  Banking on ATM as a new target in metabolic syndrome.

Authors:  Steven E Shoelson
Journal:  Cell Metab       Date:  2006-11       Impact factor: 27.287

2.  Heterozygous mutation of ataxia-telangiectasia mutated gene aggravates hypercholesterolemia in apoE-deficient mice.

Authors:  Dongfang Wu; Hong Yang; Wei Xiang; Lichun Zhou; Mingjian Shi; George Julies; Janice M Laplante; Billy R Ballard; Zhongmao Guo
Journal:  J Lipid Res       Date:  2005-05-01       Impact factor: 5.922

3.  Akt2 regulates cardiac metabolism and cardiomyocyte survival.

Authors:  Brian DeBosch; Nandakumar Sambandam; Carla Weinheimer; Michael Courtois; Anthony J Muslin
Journal:  J Biol Chem       Date:  2006-08-31       Impact factor: 5.157

Review 4.  Cell cycle checkpoints: the role and evaluation for early diagnosis of senescence, cardiovascular, cancer, and neurodegenerative diseases.

Authors:  O Golubnitschaja
Journal:  Amino Acids       Date:  2006-11-30       Impact factor: 3.520

5.  ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome.

Authors:  Jochen G Schneider; Brian N Finck; Jie Ren; Kara N Standley; Masatoshi Takagi; Kirsteen H Maclean; Carlos Bernal-Mizrachi; Anthony J Muslin; Michael B Kastan; Clay F Semenkovich
Journal:  Cell Metab       Date:  2006-11       Impact factor: 27.287

6.  Lack of ataxia telangiectasia mutated kinase induces structural and functional changes in the heart: role in β-adrenergic receptor-stimulated apoptosis.

Authors:  Cerrone R Foster; QinQin Zha; Laura L Daniel; Mahipal Singh; Krishna Singh
Journal:  Exp Physiol       Date:  2011-12-16       Impact factor: 2.969

7.  Identification of p32 as a novel substrate for ATM in heart.

Authors:  Hisakazu Kato; Seiji Takashima; Yoshihiro Asano; Yasunori Shintani; Satoru Yamazaki; Osamu Seguchi; Hiroyuki Yamamoto; Atsushi Nakano; Shuichiro Higo; Akiko Ogai; Tetsuo Minamino; Masafumi Kitakaze; Masatsugu Hori
Journal:  Biochem Biophys Res Commun       Date:  2007-12-10       Impact factor: 3.575

8.  ATM protein kinase mediates full activation of Akt and regulates glucose transporter 4 translocation by insulin in muscle cells.

Authors:  Marie-Jo Halaby; Jody C Hibma; Jinghua He; Da-Qing Yang
Journal:  Cell Signal       Date:  2008-04-26       Impact factor: 4.315

9.  ATR/ATM targets are phosphorylated by ATR in response to hypoxia and ATM in response to reoxygenation.

Authors:  Ester M Hammond; Mary Jo Dorie; Amato J Giaccia
Journal:  J Biol Chem       Date:  2003-01-07       Impact factor: 5.157

10.  Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat.

Authors:  S E Litwin; S E Katz; J P Morgan; P S Douglas
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690

View more
  2 in total

1.  Hydroxychloroquine Protects against Cardiac Ischaemia/Reperfusion Injury In Vivo via Enhancement of ERK1/2 Phosphorylation.

Authors:  Lauren Bourke; James McCormick; Valerie Taylor; Charis Pericleous; Benoit Blanchet; Nathalie Costedoat-Chalumeau; Daniel Stuckey; Mark F Lythgoe; Anastasis Stephanou; Yiannis Ioannou
Journal:  PLoS One       Date:  2015-12-04       Impact factor: 3.240

Review 2.  Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.

Authors:  Durga Prasanna Misra; Armen Yuri Gasparyan; Olena Zimba
Journal:  Rheumatol Int       Date:  2020-09-02       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.